Modernatx Revenue, Growth & Competitor Profile

DBA Moderna LLC
DBA MODERNA THERAPEUTICS INC

Company Profile & Annual Report for Modernatx

Access the complete profile.

Modernatx Fast Facts

Revenue	Over $500 million    See Exact Annual Revenue
Employees	Over 1,000Exact Company Size
Primary Industry	621511 Medical Laboratories
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing 541711 Research & Development in Biotechnology
Address	200 Technology Sq Cambridge, MA 02139

Note: Revenues for privately held companies are statistical evaluations.


Modernatx's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Modernatx's annual revenues are Over $500 million (see exact revenue data)
• What industry is the company in?
  • Modernatx is classified as operating in the Medical Laboratories industry, NAICS Code 621511.

Modernatx Annual Revenue and Growth Rate

Modernatx	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	Over $500 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Modernatx's revenues are gauged from an analysis of company filings.

Modernatx's Income Statement (based on Industry Averages)

Modernatx P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Investor Activity

Modernatx has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date	Investors	Percent Raised	Target Size
August 24, 2016	72	75%	$600 MM
Complete list of funding rounds and total amounts in the Company Report

Trademark Applications

Trademark applications show the products and services that Modernatx is developing and marketing. Modernatx's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
MNEXSPIVAX Vaccines for human use	01/04/2024
MNEXCOV Vaccines for human use	01/04/2024
MNEXSPIKE Vaccines for human use	01/04/2024

See all trademarks and details in the Full Report.

Market Share of Modernatx's Largest Competitors

A competitive analysis shows these companies are in the same general field as Modernatx, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
PHYSICIANS IMMUNODIAGNOSTIC LABORATORY	Burbank, CA	100
ACCU REFERENCE MEDICAL LAB LIMITED LIABILITY	Linden, NJ	100
CENTOGENE US	Cambridge, MA	88
LATARA ENTERPRISE	Pomona, CA	61
TELIGENT PHARMA	Vineland, NJ	46
COVID CLINIC	Huntington Beach, CA	37
VIKOR SCIENTIFIC	Charleston, SC	33
BIOTHERANOSTICS	San Diego, CA	31
SHERMAN-ABRAMS LABORATORY	Brooklyn, NY	31

Nearby Competitors

These companies are similar in business line and location to Modernatx. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
MODERNATX	Cambridge, MA	100
CENTOGENE US	Cambridge, MA	7
THRIVE EARLIER DETECTION	Cambridge, MA	5
TCR2 THERAPEUTICS	Cambridge, MA	2
SHERLOCK BIOSCIENCES	Brighton, MA	2
ABACUS INSIGHTS	Boston, MA	2

Future Competition: Modernatx's Fastest Growing Competitors

These companies are in the same general field as Modernatx and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)